Find out more about the NICE Highly Specialised Technology Evaluation Committee members by reading their biographies.
Dr Peter Jackson, PhD FRCP – Chair
Consultant Physician & Hon. Reader in Clinical Pharmacology and Therapeutics, Sheffield Teaching Hospitals NHS Foundation Trust
Doctor Jackson runs the Sheffield Hypertension service, provides acute medical services for Care of the Elderly and acts as Foundation Training Programme Director. He also plays a role locally in medicines management and chairs the Trust Medicines Safety Committee. His academic interests are in the factors that influence decisions both by prescribers and patients whether to start or stop long-term drug treatment, particularly in the elderly.
Professor Ron Akehurst, BSc (Econ) (London), Hon MFPHM
Strategic Director, BresMed
Strategic Director of BresMed Health Solutions Ltd and Professor Emeritus at The University of Sheffield in the School of Health and Related Research (ScHARR). Founder of ScHARR and Dean of School for 17 years. Academic interests are primarily in Health Technology Assessment (HTA). Published widely in Health Economics. Contributed to the development of methods of HTA. Carried out research and conducted HTAs in many different therapeutic areas.
A founding member of the National Institute for Clinical Excellence (NICE) Appraisal Committee, serving on it for 7 years; served on the NICE Topic Selection Committee; the NICE Public Health Interventions Advisory Committee and is currently a member of the NICE Diagnostics Advisory Committee and Highly Specialised Technologies Committee.
A member of the Advisory Group on National Specialised Services (AGNSS) which advises the Secretary of State for Health on organisation of services for people with very rare conditions.
Been involved in preparing HTA submissions to many bodies, including NICE, SMC, TLV, PBAC and CADTH. He has also advised healthcare companies on developing their in-house HEOR capabilities and overseas governments on implementing HTA.
Mr Sotiris Antoniou, RPS, MSc, DipMgt
Consultant Pharmacist, Cardiovascular Medicine, Barts Health NHS Trust
Sotiris is responsible for the development of cardiovascular prescribing guidelines across all of North East London as part of his role as consultant pharmacist.
He is an independent prescriber and is currently chair of the cardiac committee for United Kingdom Clinical Pharmacy Association (UKCPA). He has published extensively in the pharmacy press and has a particular interest in in improving anticoagulation for stroke prevention in atrial fibrillation. He is actively involved in the training and development of clinical pharmacists including developing a curriculum and assessment tool for advanced and consultant level specialist cardiac pharmacists working with the UKCPA and Royal Pharmaceutical Society.
Sotiris has served on NICE development groups including Unstable Angina/NSTEMI guideline, stable angina and STEMI guidelines and is an honorary senior research associate at UCL School of Pharmacy
Dr Paul Arundel
Consultant in Children’s Metabolic Bone Disease, Sheffield Children’s Hospital
Dr Paul Arundel is a full-time NHS consultant and Clinical Lead for the Paediatric Metabolic Bone Disease Service at Sheffield Children’s Hospital. His work encompasses the delivery and improvement of care to children and young people with a wide range of bone diseases through multidisciplinary team working and collaboration with partners across the UK.
He has overseen the implementation of the Highly Specialised Services for both “severe, complex and atypical osteogenesis imperfecta” and “paediatric-onset hypophosphatasia”.
Clinical and research interests include assessment and treatment of bone fragility disorders, achondroplasia and disorders of calcium and phosphate metabolism including X-linked hypophosphataemic rickets.
Senior Lecturer in Health Economics, ScHARR, The University of Sheffield.
Sarah Davis is Deputy Director of the NICE Decision Support Unit (DSU). The DSU is commissioned by NICE to provide a research and training resource to support the Institute's Technology Appraisal Programme.
She is based at the School of Health and Related Research (ScHARR) at the University of Sheffield and is a member of the ScHARR Technology Assessment Group. Her technical background is in cost-effectiveness modelling and she has a particular interest in patient-level simulation.
Prior to her role at ScHARR, she was Health Economic Lead at the National Clinical Guideline Centre, which is commissioned by NICE to develop clinical guidelines, and she maintains an interest in guideline development including the use of modelling to inform service delivery guidance.
Director of Finance, Welsh Health Specialised Services Committee
Having held Director level positions for both the NHS and Welsh Government for the last 15 years, Stuart has extensive experience of commissioning specialised health services in Wales.
He has a 31 year career in Public Service with previous experience in Local Government, NHS England (former Regional Health Authority) and in NHS Acute, Community and Mental Health Services Trusts both in England and Wales.
Stuart is a Fellow of the Chartered Association of Certified Accountants and a member of the ACCA UK Health Panel (2014 panel award winner).
Specialised Commissioning Manager, NHS England
Carrie is the Regional Programme of Care lead for internal medicine for NHS England (London Region) and Lead Commissioner for the Cardiothoracic Services Clinical Reference Group (CRG). She has worked in operational commissioning roles in London since the establishment of NHS England. She has a background in clinical audit and in the private sector.
Carrie was previously the Lead Commissioner for the Specialised Rheumatology CRG which has developed national commissioning products such as Commissioning for Quality and Innovation and Improving Value schemes.
Mr Jeremy Manuel, OBE
Solicitor; Chairman European Gaucher Alliance; Director Gauchers Association; Director European Working Group on Gaucher Disease.
Jeremy Manuel co-founded the UK Gauchers Association in 1991 and was its national Chairman until 2012 and remains a member of its Board of Directors. He was also a founding member of the European Gaucher Alliance which is an umbrella organisation of Patient Groups representing the interests of Gaucher Patients and was appointed its first Chairman in 2008. He is a Trustee of the Helen Manuel Foundation a Charitable Trust established to raise funds for research into Gauchers disease. He is also a Director (the only non-clinician or scientist) of the European Working Group on Gaucher Disease.
Through his work with the Association Jeremy has represented the interests of Gauchers patients both in the UK and abroad to clinicians, scientists, government and industry and has jointly with others contributed to peer reviewed journals and other publications.
Jeremy is a practising Lawyer (solicitor) and an accredited Commercial Mediator. He was awarded the Freedom of the City of London in 1994 and an OBE in the Queens New Year Honours List 1999 for services to the Gauchers Disease. He is also a Fellow of the Royal Society of Arts.
Dr Shehla Mohammed MD, FRCP
Consultant in Clinical Genetics and Head of Service
Shehla Mohammed is Honorary Senior Lecturer in Clinical Genetics, King’s College Hospital, and Guy’s & St. Thomas’ NHS Foundation Trust, London. She is a paediatric clinical geneticist with 22 years’ experience predominantly in rare genetic disorders and in the care of children and families with life-limiting disorders. Her clinical and research interest is in paediatric neuromuscular and DNA repair disorders.
Shehla has a range of committee experience with a number of organisations, including her current role as expert clinical adviser to the UKGTN. She contributes to advisory bodies on policy development and implementation of genomic technologies. As Head of Service of one of the largest Regional Genetics Services, Shehla has extensive experience of negotiating the establishment of new services, implementing Highly Sepcialist Service clinics and devising novel models of service delivery.
Shehla has contributed to both service and national policy development such as UKGTN Guide to Centres with specialist expertise for Rate Genetic disorders, Genomic Medicine in the UK and input into national Rare Disease Strategy.
Vice-President, Market Access, Biogen Idec
Francis Pang is Vice-President of Market Access at Biogen Idec. Francis studied health economics at the University of York (1995) followed by appointments as the inaugural Research Fellow in Pharmacoeconomics at the Centre for Health Economics, University of York and as Monbusho Scholar at the Department of Economics, Kyoto University, Japan.
Prior to joining Biogen Idec, Francis held various health economics and market access leadership roles at Abbott Laboratories, Takeda Pharmaceuticals and Shire Human Genetic Therapies. At Shire, Francis led the pilot for the development of the AGNSS (Advisory Group for National Specialised Services) process based on an evaluation of a health technology for mucopolysaccharidosis type II.
Francis's primary research interests include methods for the health technology assessment of treatments for rare diseases and the generalisability and transferability of economic evaluations across settings. Francis is currently pursuing his MBA at INSEAD.
Linn Phipps MA, MSc
Linn has served as a chair, non-executive director and lay adviser in the NHS for nearly 20 years. She takes a special interest in good governance, outcomes and how patient and public voices can be embedded into health and social care.
Currently she's a lay member on our Highly Specialised Technologies Evaluation Committee and Indicator Advisory Committee. Linn also works in consultancy as a coach, mediator and facilitator.
Dr Mark Sheehan
Oxford BRC Ethics Fellow, The Ethox Centre, University of Oxford
Mark Sheehan is Oxford NIHR Biomedical Research Centre (BRC) Ethics Fellow at the Ethox Centre and a Research Fellow at the Uehiro Centre for Practical Ethics, University of Oxford. He received his PhD in Philosophy from The Graduate Centre of the City University of New York.
He is currently a National Research Ethics Advisor for the National Research Ethics Service and a member of the Nuffield Council on Bioethics working group on research in children. He was a member of the NHS Advisory Group for National Specialised Services (AGNSS) and vice-chair of the Thames Valley Priorities Forum (MOBBB) for the South Central Strategic Health Authority. He is Associate Editor of the Journal of Medical Ethics and is a Senior Research Fellow in Philosophy at St. Benet's Hall, University of Oxford.
Dr Matt Smith
Consultant, Public Health England
Matt Smith is a consultant in public health medicine, based in Public Health England. He provides public health leadership and advice to NHS England nationally and regionally on the commissioning of specialised services. Prior to this, Matt held senior public health roles in local government and the NHS.
Dr Glenda Sobey
Consultant Dermatologist, Sheffield Children’s Hospital and Honorary Senior lecturer at the University of Sheffield
Dr Glenda J Sobey is co-founder and head of the Ehlers Danlos Syndrome National Diagnostic Service in the UK based at Sheffield Childrens’ Hospital and Honorary Senior lecturer at the University of Sheffield. Dr Sobey is a Consultant Dermatologist with qualification in Clinical Genetics. Her unit is responsible for the diagnosis of rare and atypical Ehlers Danlos Syndrome.
Dr Sobey has an active role in teaching and lectures nationally and internationally. She has published widely. She is particularly interested in promoting early diagnosis in rare disease to allow optimal outcome for patients and families.
Professor Lesley Ann Stewart
Director, NIHR Centre for Reviews and Dissemination, University of York
Lesley Stewart is Director of the NIHR Centre for Reviews and Dissemination (CRD) at the University of York. She has spent her career working in evidence synthesis, previously leading the MRC Clinical Trials Unit meta-analysis programme.
CRD produces databases of research evidence and other knowledge products, primarily to support evidence informed decision making within the NHS, but with global reach. CRD undertakes health technology assessments for the NIHR HTA programme for policy customers including NICE, and systematic reviews across a broad range of health and public health topics. Lesley is committed to the combination of methodological innovation with delivery of relevant research that meets health policy and decision makers needs and communicates research findings in an a way that is meaningful to them.
Lesley's research interests are in the conduct and methodological development of systematic reviews, particularly individual participant data (IPD) meta-analysis and she has a long-standing interest in research transparency and data sharing. She was a founding member of the Cochrane Collaboration and has been Co-convenor of the IPD Meta-analysis Methods Group since inception. She is also Co-Editor in Chief of the BMC journal Systematic Reviews and is currently President Elect of the international Society for Research Synthesis Methods.
Find out more about the committee and read papers from previous meetings.
Find out when HSTEC meetings are held and register to attend.